Ann: Xolatryp Achieves Key Clinical Milestone, page-16

means nothing if it doesn’t succeed nothing is priced in but the probability of success is high, but if it doesn’t succeed this 60 million market cap becomes a lot more valuable and NYR becomes a takeover target overnight. Especially the fact that one big pharma is in this space there will be a rush from other big pharma. Weight loss drug takeover last week from Pfizer. 7 billion dollar takeover of a drug in phase 2b and not even completed yet. Boehringer results are transformative in this space

https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-closes-73-billion-takeover-anti-obesity-drugmaker-metsera-ft-reports-2025-09-22/